Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation

Transfusion ◽  
1994 ◽  
Vol 34 (3) ◽  
pp. 226-232 ◽  
Author(s):  
S Bhatia ◽  
J McCullough ◽  
EH Perry ◽  
M Clay ◽  
NK Ramsay ◽  
...  
2002 ◽  
Vol 49 (suppl_1) ◽  
pp. 51-55 ◽  
Author(s):  
Olle Ringdén

Abstract Our substantial experience in several trials with AmBisome in adult and paediatric patients undergoing transplantation has shown this formulation of amphotericin B to be safe and effective in therapeutic and prophylactic use. AmBisome has shown a significant reduction in fungal colonization and invasive Candida infections compared with placebo in a prospec-tive, double-blind study in bone marrow transplantation, and eradication of invasive fungal infections in 86% of 14 children undergoing bone marrow transplantation. The main side effects of AmBisome use are elevations in serum potassium and creatinine, but these lead to very few withdrawals from treatment. Compared with conventional amphotericin B, AmBisome is very expensive, but its much improved safety profile and proven efficacy make it an excellent agent for management of invasive fungal disease in transplant recipients.


1994 ◽  
Vol 69 (3) ◽  
pp. 157-157 ◽  
Author(s):  
R. Martino ◽  
A. Altés ◽  
A. Sureda ◽  
S. Brunet ◽  
A. Domingo-Albós

Infection ◽  
1988 ◽  
Vol 16 (1) ◽  
pp. 19-24 ◽  
Author(s):  
Th. Schmeiser ◽  
E. Kurrle ◽  
R. Arnold ◽  
W. Heit ◽  
H. Heimpel ◽  
...  

2005 ◽  
Vol 129 (3) ◽  
pp. 366-371 ◽  
Author(s):  
Monika Roychowdhury ◽  
Stefan E. Pambuccian ◽  
Deniz L. Aslan ◽  
Jose Jessurun ◽  
Alan G. Rose ◽  
...  

Abstract Context.—Bone marrow transplantation (BMT) is used to treat various malignant and nonmalignant disorders. Pulmonary complications are some of the most common causes of mortality in BMT recipients. Poor general health and bleeding tendency frequently preclude the use of definitive diagnostic tests, such as open lung biopsy, in these patients. Objective.—To identify pulmonary complications after BMT and their role as the cause of death (COD). Design.—The autopsy and bronchoalveolar lavage (BAL) slides and microbiology studies of BMT recipients from a 7-year period were reviewed. Results.—Pulmonary complications were identified in 40 (80%) of the 50 cases. The most common complications were diffuse alveolar damage (DAD) and diffuse alveolar hemorrhage (DAH). Pulmonary complications were the sole or 1 of multiple CODs in 37 cases (74%). All complications were more common in allogeneic BMT recipients. In 19 (51%) of the 37 cases in which pulmonary complications contributed to the death, cultures were negative. Both DAD and DAH, complications commonly reported in the early post-BMT period, were seen more than 100 days after BMT in 33% and 12% of cases, respectively. Five (83%) of 6 cases of invasive pulmonary aspergillosis diagnosed at autopsy were negative for fungi ante mortem (by BAL and cultures). Conclusions.—Pulmonary complications are a significant COD in BMT recipients, many of which, especially the fungal infections, are difficult to diagnose ante mortem. The etiology of DAD and DAH is likely to be multifactorial, and these complications are not limited to the early posttransplantation period. Autopsy examination is important in determining the COD in BMT recipients.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 1704-1704
Author(s):  
Tania Michele Barreto Waisbeck ◽  
Guilherme Fleury Perini ◽  
Patricia do Carmo Della Vechia ◽  
Lidiane Soares Sodre Costa ◽  
Andrea Coletti ◽  
...  

Abstract Introduction Febrile neutropenia is one of the major causes of morbidity, treatment interruptions and mortality during oncological treatment and bone marrow transplant (BMT). The time from fever to initiation of empiric antibiotics therapy (AET) is related to the outcome of patients. Ideally, patients should receive EAT in less than one hour after fever. However, many patients fail to receive EAT in less than 1 hour due to intrahospitalar delays, and may have impact in patient outcomes. Therefore, institutional policies to ensure ideal management of these patients are recommended and fever-to-patient antibiotic delivery is one of quality control measure in our Oncology and BMT Unit. Methods We implemented a nurse-based program to reduce the time from first fever or clinical EAT indication to EAT infusion. A senior nurse was in charge of implementing the program in the Oncohematological and Bone Marrow Transplantation Unit. Several actions were implemented: (1) Data collection for comparative studies, (2) Team education (pharmacy, medical and nurses) through lectures and (3) Daily data verification to verify the accuracy of data registered in medical files; (4) Survey about patient characteristics included in this study. All patients in the unit were daily censored for neutropenia, and neutropenic patients were followed for fever or need for ATB initiation. Patients who initiated EAT on the emergency room (ER) or day clinic were excluded from the analysis. For all patients, time from EAT indication and EAT infusion was collected. Data was then classified in 4 categories: (1) Time to EAT <1 hour; (2) Time to EAT >1 hour; (3) Major data inconsistency (defined when EAT indication registered time was later than EAT infusion registered time); (4) Minor data inconsistency (defined when time to EAT infusion was registered at the same time of EAT indication). Twenty medical files were retrospectively selected for comparison. Results We present the results of the first three months after the program implementation. In the retrospective group, only 35% (7/20) of patients received EAT in less than 1 hour, 15% (3/20) of patients received EAT in more than 1 hour, and inconsistencies were seen in 50% of medical files, including 40% of minor and 10% major inconsistencies. After program implementation (n=17), the percentage of patients receiving EAT in less than 1 hour was 82% (14/17), 6% of patients received EAT >1 hour (1/17), and 12% (2/17) of patients had minor inconsistencies in registered time. No major inconsistencies were observed after the program. For good practicing analysis, we grouped patients in two groups: Ideal (EAT <1 hour) and Not Ideal (EAT>1 hour and inconsistencies in medical file registration). With this approach, we showed that Ideal group improved from 35% to 82%, and the Not Ideal group declined from 65% to 18% (p=0.007). Moreover, the median time to EAT decreased from 60 minutes (range 30-240) to 30 minutes (range 8-66) (p=0.01) Conclusions The implementation of a nurse-based program significantly increased the number of patients receiving ATB in <1 hour in an Oncohematological and Bone Marrow Transplant Unit after only 3 months. Moreover, the time to ATB initiation was significantly decreased with this policy. Our findings indicate that, despite the nursing staff recognize the importance of febrile neutropenia, monitoring process, education and constant communication are necessary for an effective treatment and for improvement the patient care. Further implementation of this program in the day clinic and ER are planned and a survey about patient education of neutropenic infections will be implemented. Disclosures: No relevant conflicts of interest to declare.


2000 ◽  
Vol 26 (5) ◽  
pp. 533-538 ◽  
Author(s):  
JS Serody ◽  
MM Berrey ◽  
K Albritton ◽  
SM O'Brien ◽  
EP Capel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document